{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT02997228","nct_id":"NCT02997228","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02997228. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. (CLOSED TO ACCRUAL)","label":"Arm I (bevacizumab, mFOLFOX6)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.","label":"Arm II (atezolizumab)","type":"EXPERIMENTAL"},{"description":"Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.","label":"Arm III (atezolizumab, bevacizumab, mFOLFOX6)","type":"EXPERIMENTAL"}],"collaborators":["NRG Oncology"],"completion_date":{"date":"2027-06-01","type":"ESTIMATED"},"conditions":["Metastatic Colorectal Adenocarcinoma","Stage IV Colorectal Cancer AJCC v7"],"enrollment":{"count":120,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Atezolizumab","otherNames":["MPDL 3280A","MPDL 328OA","MPDL-3280A","MPDL3280A","MPDL328OA","RG 7446","RG-7446","RG7446","RO 5541267","RO-5541267","RO5541267","Tecentriq"],"type":"DRUG"},{"name":"Bevacizumab","otherNames":["ABP 215","ABP-215","ABP215","Alymsys","Anti-VEGF","Anti-VEGF Humanized Monoclonal Antibody","Anti-VEGF Monoclonal Antibody SIBP04","Anti-VEGF rhuMAb","Avastin","Avegra","Avzivi","Aybintio","BAT 1706","BAT-1706","BAT1706","BAT1706 Biosimilar","Bevacizumab awwb","Bevacizumab Biosimilar ABP 215","Bevacizumab Biosimilar BAT1706","Bevacizumab Biosimilar BEVZ92","Bevacizumab Biosimilar BI 695502","Bevacizumab Biosimilar CBT 124","Bevacizumab Biosimilar CT-P16","Bevacizumab Biosimilar FKB238","Bevacizumab Biosimilar GB-222","Bevacizumab Biosimilar HD204","Bevacizumab Biosimilar HLX04","Bevacizumab Biosimilar IBI305","Bevacizumab Biosimilar LY01008","Bevacizumab Biosimilar MB02","Bevacizumab Biosimilar MIL60","Bevacizumab Biosimilar Mvasi","Bevacizumab Biosimilar MYL-1402O","Bevacizumab Biosimilar QL 1101","Bevacizumab Biosimilar QL1101","Bevacizumab Biosimilar RPH-001","Bevacizumab Biosimilar SCT501","Bevacizumab Biosimilar Zirabev","Bevacizumab-adcd","Bevacizumab-aveg","Bevacizumab-awwb","Bevacizumab-aybi","Bevacizumab-bvzr","Bevacizumab-byva","Bevacizumab-equi","Bevacizumab-maly","Bevacizumab-nwgd","Bevacizumab-onbe","Bevacizumab-tnjn","BP102","BP102 Biosimilar","Byvasda","CT P16","CT-P16","CTP16","Equidacent","FKB 238","FKB-238","FKB238","HD204","IBI 305","IBI-305","IBI305","Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer","Jobevne","MB 02","MB-02","MB02","Mvasi","MYL-1402O","Onbevzi","Oyavas","PF 06439535","PF-06439535","PF06439535","QL1101","Recombinant Humanized Anti-VEGF Monoclonal Antibody","rhuMab-VEGF","SCT501","SIBP 04","SIBP-04","SIBP04","Vegzelma","Zirabev"],"type":"BIOLOGICAL"},{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Fluorouracil","otherNames":["5 Fluorouracil","5 Fluorouracilum","5 FU","5-Fluoro-2,4(1H, 3H)-pyrimidinedione","5-Fluorouracil","5-Fluracil","5-Fu","5FU","AccuSite","Carac","Fluoro Uracil","Fluouracil","Flurablastin","Fluracedyl","Fluracil","Fluril","Fluroblastin","Ribofluor","Ro 2-9757","Ro-2-9757"],"type":"DRUG"},{"name":"Leucovorin","otherNames":["Folinic acid"],"type":"DRUG"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Oxaliplatin","otherNames":["1-OHP","Ai Heng","Aiheng","Dacotin","Dacplat","Diaminocyclohexane Oxalatoplatinum","Eloxatin","Eloxatine","Elplat","JM 83","JM-83","JM83","Oxalatoplatin","Oxalatoplatinum","RP 54780","RP-54780","RP54780","SR 96669","SR-96669","SR96669"],"type":"DRUG"},{"name":"Positron Emission Tomography","otherNames":["Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","PT"],"type":"PROCEDURE"},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"],"type":"OTHER"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-10-26","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-06-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS)","timeFrame":"From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years"}],"references":[{"citation":"Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ, Cole SW, Khalil M, Devanna S, Zuckerman DS, Hong TS, Henry NL, Ganz PA, Blanke CD, Wolmark N, Overman MJ. COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. J Clin Oncol. 2026 Oct 10;44(29):2824-2834. doi: 10.1200/JCO-25-03052. Epub 2026 Jul 29.","pmid":"42525921","type":"DERIVED"}],"start_date":{"date":"2018-01-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","url":"https://clinicaltrials.gov/study/NCT02997228"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02997228"}